American Diversified Holdings’ GlucoGuard hires global CRO for FDA-required patient studies

Reuters04-01
<a href="https://laohu8.com/S/ADHC">American Diversified</a> Holdings’ GlucoGuard hires global CRO for FDA-required patient studies
  • American Diversified Holdings GlucoGuard unit retained a global contract research organization to begin FDA-required patient studies.
  • Study will use Dexcom continuous glucose monitoring to record glucose levels before and after glucose administration.
  • Work targets FDA concerns tied to aspiration risk in sleeping patients plus proof of glucose increases from hypoglycemic to normal range.
  • Company flagged potential international expansion opportunities, citing China and India.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. American Diversified Holdings Corporation published the original content used to generate this news brief via Newsfile (Ref. ID: 202604010830NEWSFILECNPR____20260401_290821_1) on April 01, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment